Objective: To study whether tibolone affects lipid profile and diffused intima media thickness (IMT) of the common carotid arteries (CCA) in postmenopausal women (PMW). Methods: Twenty-two PMW and 20 premenopausal women participated in the study. The PMW were randomly divided into 11 women who did not receive any treatment and 11 women who received tibolone (2.5 mg once a day). Results: After 6 months the treated women had lipoprotein(a) (Lpa), total-cholesterol (total-C), and LDL-cholesterol (LDL-C) levels lower than before, while in the non-treated women Lpa was increased. The IMT of CCA was unmodified in the treated women, whereas it increased in non-treated women. Conclusions: This preliminary study suggests that a 6-month tibolone treatment could counteract the increase of the IMT of CCA observed in untreated PMW.

1.
Burke GL, Evans GW, Riley WA, et al: Arterial wall thickness is associated with prevalent cardiovascular disease in middle aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995;26:386–391.
2.
Hirvonen E, Malkonen M, Manninen V: Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981;304:560–563.
3.
Chambless LE, Heiss G, Folsom AR, et al: Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the ARIC Study 1987–1993. Am J Epidemiol 1997;146:483–494.
4.
Espeland MA, Applegate W, Furberg CD, Lefkowitz D, Rice L, Hunninghake D: Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women: ACAPS Investigators: Asymptomatic Carotid Atherosclerosis Progression Study. Am J Epidemiol 1995;142:1011–1019.
5.
Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM: Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501–1510.
6.
Karas RH, Patterson BL, Medelsohn ME: Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994;89:1943–1950.
7.
van der Vies J: Pharmacological studies with ((17α,17α)-17 hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one) (Org OD14). Maturitas 1987;1(suppl):15–24.
8.
Morris EP, Wilson PO, Robinson J, Rymer JM: Long term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 1999;106:954–959.
9.
Colacurci N, Mele D, De Franciscis P, Costa V, Fortunato N, De Seta L: Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol 1998;80:235–238.
10.
Haenggi W, Riesen W, Birkhauser MH: Postmenopausal hormone replacement therapy with tibolone decreases serum lipoprotein(a). Eur J Clin Chem Clin Biochem 1993;31:645–650.
11.
Crona N, Silfverstolpe G, Samsioe G: A double-blind cross-over study on the effects of Org OD14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinol (Copenh) 1983;102:451–455.
12.
Cagnacci A, Mallus E, Tuveri F, Cirillo R, Setteneri AM, Melis GB: Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1997;82:251–253.
13.
Erenus M, Ilhan AH, Elter K: Effect of tibolone treatment on intima-media thickness and the resistive indices of the carotid arteries. Fertil Steril 2003;79:268–273.
14.
Derogatis LR, Lipman RS, Covi L: SCL 90 and Outpatient Psychiatric Rating Scale: Preliminary Report. ECDEU Assessment Manual. DHEW Publication. Washington, US Government Printing Office, 1976, pp 313–331.
15.
Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R: Intimal plus media thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation 1986;74:1399–1406.
16.
Spencer CP, Whitehead MI: Endometrial assessment re-visited. Br J Obstet Gynaecol 1999;106:623–632.
17.
Crouse JR: Association of arterial wall thickening and coronary disease; in Touboul PJ, Crouse JR (eds): Intima-media Thickness and Atherosclerosis: Predicting the Risk? New York, Parthenon, 1997, pp 105–115.
18.
Veller MG, Fisher CM, Nicolaides AN, et al: Measurement of the ultrasonic intima-media complex thickness in normal subjects. J Vasc Surg 1993;17:719–725.
19.
Zandberg P, Peters JL, Demacker PN, Smit MJ, de Reeder EG, Meuleman DG: Tibolone prevents atherosclerotic lesion formation in cholesterol-fed ovariectomized rabbits. Arterioscler Thromb Vasc Biol 1998;18:1844–1854.
20.
Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens G: Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986;17:942–945.
21.
Koltringer P, Jurgens G: A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis 1985;58:187–198.
22.
Jackson G: Tibolone and cardiovascular system. Eur Heart J Suppl 2001;3:M17–M21.
23.
Crook D: Lipid predictors of coronary heart disease and tibolone users. Eur Heart J Suppl 2001;3:M22–M26.
24.
Paoletti AM, Floris S, Mannias M, et al: Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. J Clin Endocrinol Metab 2001;86:608–612.
25.
Paoletti AM, Pilloni M, Orrù M, et al: Efficacy and safety of oral and transdermal hormonal replacement treatment containing levonorgestrel. Maturitas 2002;42:137–147.
26.
Writing Group for the Women’s Health Initiative Investigators (WHI). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–333.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.